Table 2.
Comparison of clinical manifestations and laboratory features between AML patients with low and high mRNA expression of 2Ig B7-H3 (2Ig)
| Patient’s parameters | The whole AML patients |
||
|---|---|---|---|
| 2Iglow (n = 32) | 2Ighigh (n = 36) | P | |
| Sex, male/female | 19/13 | 17/19 | 0.316 |
| Median age, years (range) | 55 (15–80) | 66 (20–93) | 0.026 |
| Median WBC, ×109 /L (range) | 28.2 (0.8–136.1) | 18.7 (0.8–207.5) | 0.468 |
| Median Hb, g/L (range) | 88 (45–126) | 86 (49–141) | 0.672 |
| Median Plt, ×109 /L (range) | 31 (3–192) | 41 (5–382) | 0.555 |
| BM blasts, % (range) | 50.0 (3.0*-94.0) | 61.3 (16.5*-93.5) | 0.414 |
| FAB classification | 0.371 | ||
| M0 | 0 (0.0%) | 2 (5.6%) | |
| M1 | 1 (3.1%) | 2 (5.6%) | |
| M2 | 13 (40.6%) | 15 (41.7%) | |
| M3 | 5 (15.6%) | 2 (5.6%) | |
| M4 | 9 (28.1%) | 6 (16.7%) | |
| M5 | 4 (12.5%) | 8 (22.2%) | |
| M6 | 0 (0.0%) | 1 (2.8%) | |
| Karyotype | 0.361 | ||
| Normal | 12 (37.5%) | 13 (36.1%) | |
| t(8;21) | 2 (6.3%) | 3 (8.3%) | |
| t(16;16) | 2 (6.3%) | 0 (0.0%) | |
| t(15;17) | 5 (15.6%) | 2 (5.6%) | |
| +8 | 1 (3.1%) | 2 (5.6%) | |
| −5/5q- | 0 (0.0%) | 2 (5.6%) | |
| −7/7q- | 0 (0.0%) | 1 (2.8%) | |
| t(9;22) | 0 (0.0%) | 1 (2.8%) | |
| Complex | 3 (9.4%) | 6 (16.7%) | |
| Others | 3 (9.4%) | 5 (13.9%) | |
| Not available | 4 (12.5%) | 1 (2.8%) | |
| Karyotype classification | 0.056 | ||
| Favorable | 9 (28.1%) | 5 (13.9%) | |
| Intermediate | 16 (50.0%) | 19 (52.8%) | |
| Poor | 3 (9.4%) | 11 (30.6%) | |
| Not available | 4 (12.5%) | 1 (2.8%) | |
| Gene Mutation | |||
| NPM1 (+/-) | 9/21 | 2/31 | 0.012 |
| CEBPA (+/-) | 8/22 | 5/28 | 0.259 |
| FLT3-ITD (+/-) | 3/27 | 10/23 | 0.047 |
| c-KIT (+/-) | 1/29 | 2/31 | 1.000 |
| N/K-RAS (+/-) | 4/26 | 6/27 | 0.857 |
| IDH1/2 (+/-) | 2/28 | 5/28 | 0.504 |
| DNMT3A (+/-) | 3/27 | 3/30 | 1.000 |
| U2AF1 (+/-) | 3/27 | 1/32 | 0.538 |
| SRSF2 (+/-) | 3/27 | 2/31 | 0.912 |
| SETBP1 (+/-) | 2/28 | 1/32 | 0.933 |
| TP53 (+/-) | 1/29 | 3/30 | 0.675 |
| CR (+/-) | 19/12 | 12/23 | 0.028 |
*:Diagnosis was done in regards to the World Health Organization criteria for patients with low percentage blasts (< 20%) in BM. The cytogenetic aberrations t (15; 17) (q22; q12), were also detected in these patients. Abbreviations: AML = acute myeloid leukemia; WBC = white blood cells; Hb = hemoglobin; Plt = platelets; BM = bone marrow; CR = complete remission. P values were determined using χ2 test for the sex, karyotype, common gene mutations and CR rates after standard induction therapy for 2 cycles, and applying Mann-Whitney’s U test for the age, WBC, Hb, Plt and BM blasts.